For the first time, we found that simvastatin could significantly inhibit IL-6 induced proliferation and metastasis of RCC cells, attenuate IL-6-induced JAK2 activation, and subsequently decrease the phosphorylation of STAT3 both in vitro and in vivo. Here, STAT3 is linked to renal cell carcinoma.